TCGX has closed TCGX Asia Life Sciences Fund I at USD 600 million, an oversubscribed vehicle backed by a diverse group of international institutional investors and focused on innovative biotechnology companies across Asia, marking the firm's formal expansion into the region with new offices in Shanghai and Hong Kong. The Asia fund operates independently from TCGX's flagship Europe and US-focused funds but coordinates closely with them, allowing the investment team to combine regional specialisation with global deal sourcing and portfolio support across different stages of company development.

The fund's thesis is that Asia, and particularly China, has become a major source of global biotech innovation, with strong entrepreneurial talent, growing pipeline quality and an increasingly mature ecosystem for translating science into commercial medicines. TCGX aims to build long-term, deep partnerships with high-potential Asian companies, leveraging its investment management, technical diligence and global industry networks to accelerate innovation and globalisation, a positioning that reflects the broader shift of crossover and specialist life-science capital toward Chinese and Asian assets as out-licensing, clinical execution and regional commercialisation become more competitive.